2μg (R: reducing condition, N: non-reducing condition).
Biotinylated CD20 Flag&Avi Tag Full Length Protein, Human (Detergent)
Biotinylated CD20 Flag&Avi Tag Full Length Protein, Human (Detergent)
Price:
Regular price
$1,655 USD
Regular price
Sale price
$1,655 USD
Unit price
per
For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details
Product Details
Product Details
Product Specification
| Species | Human |
| Synonyms | MS4A1 |
| Accession | P11836 |
| Concentration | 1 mg/mL |
| Amino Acid Sequence | Met1–Pro297 with a Flag&Avi Tag at the C-terminus. |
| Expression System | HEK293 |
| Molecular Weight | 40 kDa (Reducing) |
| Purity | ＞85% by SDS-PAGE |
| Conjugation | Biotin |
| Tag | Flag Tag, Avi Tag |
| Physical Appearance | Liquid |
| Storage Buffer | 25 mM Hepes, pH7.5, 150 mM NaCl, 0.006%GDN |
| Stability & Storage | Stable for 3 months upon stored at -80℃ from the date of receipt. And avoid repeated freeze-thaws cycles. |
| Reference | 1. Rougé L, Chiang N, Steffek M, Kugel C, Croll TI, Tam C, Estevez A, Arthur CP, Koth CM, Ciferri C, Kraft E, Payandeh J, Nakamura G, Koerber JT, Rohou A. Structure of CD20 in complex with the therapeutic monoclonal antibody rituximab. Science. 2020 Mar 13;367(6483):1224-1230. |
Background
CD20 is a B-cell-specific membrane protein encoded by MS4A1 (chromosome 11q12), belonging to the MS4A family. It has four transmembrane helices and a key extracellular epitope (¹⁷⁰ANPSE¹⁷⁴), forming a tight homodimer that lacks a transmembrane pore, arguing against direct ion‑channel function. CD20 is expressed from pre‑B to mature B cells, lost on plasma cells, and highly overexpressed on malignant B cells in lymphomas, chronic lymphocytic leukaemia (CLL) and autoimmune diseases, establishing it as a validated therapeutic target.
Anti‑CD20 monoclonal antibodies fall into two types. Type I (rituximab, ofatumumab) bind two Fabs per dimer through homotypic Fab–Fab interactions, potently activating complement-dependent cytotoxicity (CDC). Type II (obinutuzumab) bind with 1:2 stoichiometry, showing reduced CDC but enhanced direct killing. These antibodies have transformed treatment, though resistance and relapse persist. Recent cryo‑EM structures (2.6–3.3 Å) have revealed the molecular basis of these differential binding modes, providing a framework for rationally designing next‑generation CD20‑targeted immunotherapies.
Picture
Picture
SDS-PAGE
ELISA
Immobilized Anti-CD20 Monoclonal Antibody (Rituximab) (Cat. No. S0B0570) at 2 μg/mL (100 μL/well) can bind Biotinylated CD20 Flag&Avi Tag Full Length Protein, Human (Detergent) (Cat. No. UA060040) with a linear range of 0.43-5.3 ng/mL.
Immobilized Anti-Human CD20 Monoclonal Antibody (Ofatumumab) (Cat. No. UA016165) at 2 μg/mL (100 μL/well) can bind Biotinylated CD20 Flag&Avi Tag Full Length Protein, Human (Detergent) (Cat. No. UA060040) with a linear range of 33.92-41.79 ng/mL.
Immobilized Anti-Human CD20 Monoclonal Antibody (Obinutuzumab) (Cat. No. S0B7128) at 2 μg/mL (100 μL/well) can bind Biotinylated CD20 Flag&Avi Tag Full Length Protein, Human (Detergent) (Cat. No. UA060040) with a linear range of 0.438-0.554 ng/mL.
